Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding ’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information. Is the behavior connected to dementia, or was it ...

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

In early-stage Alzheimer's, changes in abilities or behavior may be minor and only noticeable to family and close friends. Some symptoms typify this stage.

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Dietary supplementation with the amino acid L-serine may help reduce the memory loss associated with Alzheimer's disease.

Columnist Ray Burow clarifies some common misconceptions about Alzheimer's disease, particularly that it's a type of mental illness.

The small snacks available in the U.S. and U.K. encourage people with Alzheimer's and dementia to increase their water intake.

Read about a study finding a single, low-dose of methylene blue in healthy people boosted their short-term memory by activating relevant brain regions.

The FDA has approved BrainSee, a software for predicting Alzheimer's dementia in people with mild cognitive impairments.